Half-Year Tally in Clinical Diagnostics
Executive Summary
The top seven IVD manufacturers had lackluster 4% growth (in local currency) during the first half of 2003, compared to the same period in 2002, but the weaknesses were not evenly distributed. Perhaps the largest story in diagnostics these days is the surprising deterioration of the self-glucose testing market, one of the largest and most profitable sectors of the industry, and until recently, its biggest driver of growth.
You may also be interested in...
Two Rising Stars in Glucose Testing
Despite its attraction, diabetes glucose monitoring remains a tough field for newcomers, who face competition from four major-league, entrenched players. But two of the newer entrants appear to be succeeding--not because of revolutionary technology, but because of partnering savvy, efficient execution, and technological competence. Analysts expect Inverness Medical's symbiotic relationship with LifeScan to help Inverness's diabetes sales grow 30% a year as LifeScan pushes Inverness-made products as a major part of its fight to regain its market leadership. Home Diagnostics Inc.'s success with co-branding raises the prospect that discounting, until now not a significant factor, will become much more common in the field.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.